Solifenacin

Revision as of 00:34, 23 January 2009 by Jacob Keane-Candib (talk | contribs) (→‎Mechanism of action)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Solifenacin
File:Solifenacin.svg
Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]
Pregnancy
category
  • AU: B3
  • US: C (Risk not ruled out)
Routes of
administration
Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability90%
Protein binding98%
MetabolismHepatic (CYP3A4-mediated)
Elimination half-life45 to 68 hours
ExcretionRenal (69.2%) and fecal (22.5%)
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC23H26N2O2
Molar mass362.465 g/mol

WikiDoc Resources for Solifenacin

Articles

Most recent articles on Solifenacin

Most cited articles on Solifenacin

Review articles on Solifenacin

Articles on Solifenacin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Solifenacin

Images of Solifenacin

Photos of Solifenacin

Podcasts & MP3s on Solifenacin

Videos on Solifenacin

Evidence Based Medicine

Cochrane Collaboration on Solifenacin

Bandolier on Solifenacin

TRIP on Solifenacin

Clinical Trials

Ongoing Trials on Solifenacin at Clinical Trials.gov

Trial results on Solifenacin

Clinical Trials on Solifenacin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Solifenacin

NICE Guidance on Solifenacin

NHS PRODIGY Guidance

FDA on Solifenacin

CDC on Solifenacin

Books

Books on Solifenacin

News

Solifenacin in the news

Be alerted to news on Solifenacin

News trends on Solifenacin

Commentary

Blogs on Solifenacin

Definitions

Definitions of Solifenacin

Patient Resources / Community

Patient resources on Solifenacin

Discussion groups on Solifenacin

Patient Handouts on Solifenacin

Directions to Hospitals Treating Solifenacin

Risk calculators and risk factors for Solifenacin

Healthcare Provider Resources

Symptoms of Solifenacin

Causes & Risk Factors for Solifenacin

Diagnostic studies for Solifenacin

Treatment of Solifenacin

Continuing Medical Education (CME)

CME Programs on Solifenacin

International

Solifenacin en Espanol

Solifenacin en Francais

Business

Solifenacin in the Marketplace

Patents on Solifenacin

Experimental / Informatics

List of terms related to Solifenacin

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Solifenacin (rINN), marketed as solifenacin succinate under the trade name Vesicare, is a urinary antispasmodic of the anticholinergic class. It is used in the treatment of overactive bladder with or without urge incontinence.

Pharmacology

Mechanism of action

Solifenacin is a competitive muscarinic acetylcholine receptor antagonist. The binding of acetylcholine to these receptors, particularly the M3 receptor subtype, plays a critical role in the contraction of smooth muscle. By preventing the binding of acetylcholine to these receptors, solifenacin reduces smooth muscle tone in the bladder, allowing the bladder to retain larger volumes of urine and reducing the number of micturition, urgency and incontinence episodes. Thanks to a long elimination half life, once-a-day dose can offer 24 hour control of the urinary bladder smooth muscle tone.

Contraindications

Solifenacin should not be taken by people with a history of previous hypersensitivity to it, urinary retention, gastric retention, uncontrolled or poorly controlled closed-angle glaucoma, or severe liver disease (Child-Pugh class C). It is also contraindicated in long QT syndrome, as solifenacin,like tolterodine and darifenacin, binds to HERG channels and may prolong the QT interval.

Interactions

Solifenacin is metabolized in the liver by the cytochrome P450 enzyme CYP3A4. When administered concomitantly with drugs that inhibit CYP3A4, such as ketoconazole, the metabolism of solifenacin is impaired, leading to an increase in its concentration in the body and a reduction in its excretion. The manufacturer recommends that the dosage of solifenacin not exceed 5 mg a day if it is taken with a potent CYP3A4 inhibitor.

As stated above, solifenacin may also prolong the QT interval. Therefore, it should not be administered concomitantly with drugs which also have this effect, such as moxifloxacin or pimozide.

Side effects

The most common side effects of solifenacin are dry mouth, blurred vision, and constipation. As all anticholinergics, solifenacin may rarely cause heat prostration due to decreased perspiration.

Pharmacoeconomics

In a study of cost-effectiveness analysis, the average medical cost per overactive bladder patient with successful treatment is reported to be lowest for 5 mg solifenacin ($6863 per annum) among anticholinergic drugs to treat overactive bladder in the united states (Pharmacotherapy 2006, 26 1694-1702).

Template:SIB

de:Solifenacin

Template:WH Template:WikiDoc Sources